Fluoxetine Half-Life
Fluoxetine has an elimination half-life of 1-3 days after acute administration and 4-6 days after chronic administration, while its active metabolite norfluoxetine has a significantly longer elimination half-life of 4-16 days after both acute and chronic administration 1, 2.
Clinical Implications of the Extended Half-Life
The prolonged elimination kinetics of fluoxetine distinguish it from other SSRIs and create several important clinical considerations:
Steady-State Achievement and Drug Accumulation
- Steady-state concentrations are reached only after 4-5 weeks of continuous dosing 1, 2
- After 30 days of 40 mg/day dosing, plasma concentrations reach 91-302 ng/mL for fluoxetine and 72-258 ng/mL for norfluoxetine 1
- This is markedly different from other SSRIs (sertraline, paroxetine, citalopram), which typically reach steady state within 1 week 3
Persistent Drug Activity After Discontinuation
Active drug substance persists in the body for weeks after stopping fluoxetine, depending on individual patient characteristics, previous dosing regimen, and length of therapy 1, 2. This creates a critical safety consideration:
- A 5-week washout period is required before initiating MAOIs or other serotonergic agents to avoid serotonin syndrome 1
- Drug interactions can occur for weeks after fluoxetine discontinuation 1
Dosing Interval Flexibility
The extended half-life permits once-daily dosing for most patients 4. The long half-life also provides a buffer if patients miss occasional doses, as plasma concentrations decrease only slightly 5.
Special Population Considerations
Hepatic Impairment
In cirrhotic patients, fluoxetine half-life extends to a mean of 7.6 days (compared to 2-3 days in healthy subjects), while norfluoxetine half-life extends to 12 days (compared to 7-9 days normally) 1, 2. Lower or less frequent dosing is mandatory in patients with liver disease 1.
CYP2D6 Poor Metabolizers
Approximately 7% of the population are CYP2D6 poor metabolizers who achieve higher S-fluoxetine concentrations but lower S-norfluoxetine concentrations at steady state 1, 2. However, the total sum of active enantiomers remains similar to normal metabolizers, so net pharmacodynamic activity is essentially unchanged 1.
Pediatric and Geriatric Patients
- Elderly patients: Single-dose studies show no significant differences, though the long half-life makes single-dose studies inadequate to rule out altered pharmacokinetics in elderly patients with systemic illness or polypharmacy 1
- Renal impairment: Does not significantly affect fluoxetine pharmacokinetics; dose adjustment is not routinely necessary 1
Dose Titration Timing
Because of the extended half-life, dose adjustments should occur at approximately 3-4 week intervals when prescribing fluoxetine, compared to 1-2 week intervals for shorter half-life SSRIs like sertraline or citalopram 4. This allows adequate time to reach new steady-state concentrations before further titration.